This review provides a historical context and future perspective on the development of antiarrhythmic drugs, highlighting the limitations of traditional channel-selective agents and the need for novel therapeutic approaches.
No takes yet. Share an insight, caveat, or question.
Highlights need for novel antiarrhythmic approaches; leaves open which targets merit prospective trials.
Michael K. Pugsley (2002) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: